Ligand Pharmaceuticals Inc. news

   Watch this stock
Showing stories 1 - 10 of about 100   

Articles published

LGND 108.26 +0.48 (0.45%)
price chart
Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Sees Large Inflow ...
On a different note, The Company has disclosed insider buying and selling activities to the Securities Exchange, The Officer (VP, Gen.
Longs Vs. Shorts In Ligand Pharma: Roth Capital Analyst Squares Up Against ...
In a report rolled out Wednesday, Roth Capital analysts Joseph Pantginis and Assaf Vestin reiterated a Buy rating and $135.00 price target on shares of Ligand Pharmaceuticals Inc. (NASDAQ: LGND), after partner Viking Therapeutics Inc (NASDAQ: VKTX) ...
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Analyst Rating in Focus  Investor Newswire
Ligand Pharmaceuticals Inc. (LGND) Enters into Commercial License and Supply ...
Ligand Pharmaceuticals Inc. (NASDAQ:LGND) announces it has entered into a global license and supply agreement with Sanofi SA (ADR) (NYSE:SNY) to utilize Captisol in the development and commercialization of SAR-125844, a potent MET kinase ...
Ligand Pharmaceuticals Inc.: Ligand Enters into Commercial License and ...  The Wall Street Transcript
Ligand Enters into Commercial License and Supply Agreement with Sanofi for ...  MarketWatch
Company Update (NASDAQ:LGND): Ligand Pharmaceuticals Inc. Receives CHMP ...
Ligand Pharmaceuticals Inc. (NASDAQ:LGND) announces the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for Revolade´┐Ż (eltrombopag), a Novartis product, for the treatment ...
Ligand Pharmaceuticals Inc Blair William & CoIl Bought New Stake
Ligand Pharmaceuticals Inc. (NASDAQ:LGND) is a newly disclosed equity position for this institutional investor and the filing was required due to activity on December 31, 2014.
Ligand Pharmaceuticals Inc (LGND) Files Form 4 Insider Selling : John L ...
Ligand Pharmaceuticals Inc (LGND): John L Higgins , Chief Executive Officer of Ligand Pharmaceuticals Inc sold 10,000 shares on Jun 9, 2015.
John Higgins just Unloaded 10000 shares of Ligand Pharmaceuticals Inc ...  OctaFinance.com
Will Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Surprise This Quarter?  Investor Newswire
Ligand Pharmaceuticals Inc. (NASDAQ:LGND) announces that company executives ...
Ligand Pharmaceuticals Inc. (NASDAQ:LGND) opened trading today as $98.60 and is trading in the range of 96.13-98.66 today. Ligand's current market cap stands at $1.94 billion.
Cantor Fitzgerald Recommendation on Ligand Pharmaceuticals Incorporated ...  Insider Trading Report
Warning Ligand Pharmaceuticals Inc. (NASDAQ:LGND) optimists! Charles Berkman ...
Counsel & Secretary - made a sale of 14,067 shares of Ligand Pharmaceuticals Inc, with a market value exactly $ 1,394,610 based on an average price-per-share of $ 99.1.
Insider Selling: Ligand Pharmaceuticals VP Sells 14067 Shares of Stock (LGND)  Dakota Financial News
Ligand Pharmaceuticals VP Charles S. Berkman Sells 14067 Shares (LGND)  sleekmoney
Matthew Foehr, President and COO of Ligand Pharmaceuticals Inc. (NASDAQ:LGND ...
12,500 shares of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) 107.78 +0.92 0.86% were sold by Matthew Foehr, the company's President and COO.
Ligand Pharmaceuticals Inc (LGND) Files Form 4 Insider Selling : Matthew W ...  Insider Trading Report
Analysts' Recent Ratings Updates for Ligand Pharmaceuticals (LGND)  sleekmoney
Ligand Pharmaceuticals Inc (LGND) Files Form 4 Insider Selling : Matthew W ...
Ligand Pharmaceuticals Inc (LGND): Matthew W Foehr , President and COO of Ligand Pharmaceuticals Inc sold 23,046 shares on Jun 22, 2015.
Matthew Foehr Unloaded 23046 Shares of Ligand Pharmaceuticals Inc. (NASDAQ:LGND)  OctaFinance.com
Ligand Pharmaceuticals Receives Buy Rating from Roth Capital (LGND)  The Legacy